Vicapsys Life Sciences, Inc. (VICP)

Market Cap	8.66M
Revenue (ttm)	n/a
Net Income (ttm)	-1.42M
Shares Out	19.50M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.444
Previous Close	0.444
Day's Range	n/a
52-Week Range	0.444 - 3.000
Beta	-5.59
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About VICP

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics Internati...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 2
• Stock Exchange: OTCMKTS
• Ticker Symbol: VICP